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Abstract
Chronic kidney disease (CKD) is a prevalent condition in many countries, and it is estimated that
over $1 trillion is spent globally on end-stage renal disease (ESRD) care. There is a clear clinical
and economic rationale for designing timely and appropriate health system responses to limit
progression from CKD to ESRD. This article reviews the gaps in our knowledge about which
early CKD interventions are appropriate, the optimal time to intervene, and what model of care to
adopt.
The available diagnostic tests exhibit key limitations. Clinical care may improve if early-stage (1–
3) CKD with risk for progression towards ESRD is differentiated from early CKD that is unlikely
to advance. It is possible that CKD should be re-conceptualized as a part of primary care.
Additional research is needed to better understand the risk factors for CKD progression. Systems
modelling can be used to evaluate the impact of different care models on CKD outcomes and
costs. The US Indian Health Service experience has demonstrated that an integrated, system-wide
approach, even in an underfunded system, can produce significant benefits.
Introduction
Chronic kidney disease (CKD) is a common condition characterized by evidence of kidney
damage or dysfunction, as well as an increased risk of cardiovascular disease.1, 2 CKD is
currently classified based on a patient's estimated glomerular filtration rate (eGFR) and
urinary albumin excretion rate (AER) (Table 1);3 clinicians look for markers of renal
damage (e.g., abnormalities of urinary sediment or organ structure) to diagnose CKD in
people with eGFRs of ≥60 mL/min/1.73 m2. Diabetes and hypertension cause up to two-
thirds of CKD;4 less common causes include glomerulonephritis, nephrolithiasis, and
polycystic kidney disease. In a small proportion of cases, progressive kidney damage leads
to end-stage renal disease (ESRD). ESRD patients require dialysis or kidney transplantation
to survive. The rate of CKD progression varies between patients depending on disease
etiology and pathology.5, 6
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In the US, the prevalence rate (95% CI) of CKD among non-institutionalized adults
increased from 12.0% (10.4% – 13.5%) to 14.0% (12.4% – 15.7%) between 1988–94 and
1999–2004; this rise may have flattened off, with recent data (2007–2012) suggesting that
the rate is now 13.7% (12.1% – 15.2%).7 CKD is prevalent in most high-income
countries,1, 5 although data suggest that the UK rate decreased from 6.7% to 6.0% between
2003 and 2009–2010.8
In many high-income countries, ESRD patients represent <0.1% of the total population, but
account for between 1% and 2% of health-care spending.9 It is estimated that over $1 trillion
is spent worldwide on ESRD care.10 There is a clear clinical and economic rationale for
designing progression from CKD to ESRD.11–14 This article outlines the gaps in our
knowledge about which early CKD interventions are appropriate, the optimal time to
intervene, and what model of care to adopt.
CKD diagnosis
The first step in outlining an intervention strategy is to define which patients have early
CKD. The publication of the first CKD guidelines in 2002 by the National Kidney
Foundation, a US voluntary health organization, was an important step to bring policy
attention to CKD. These guidelines, referred to as the KDOQI guidelines, were adopted by
countries and institutions worldwide and form the basis for CKD classification.
Based on current prevalence estimates,7 44.6 million people in the US – including 33.6% of
people aged 60 years or older – have CKD. Over 95% of these individuals are classified as
having stages 1–3, prompting some to call the current situation a “silent epidemic”10 and the
“tip of the iceberg.”15 A recent study suggested that a person born in the US today has a
lifetime risk of developing CKD stages 3a+, 3b+, 4+, and ESRD of 59.1%, 33.6%, 11.5%,
and 3.6%, respectively.16 The prevalence rates are based on eGFR readings – a proxy
measure of renal function – usually calculated using the CKD-EPI (CKD Epidemiology
Collaboration) or MDRD Study (Modification of Diet in Renal Disease) formulae.
Albuminuria levels provide supplemental information.
eGFR equations and age-related decline in renal function
These high lifetime risks for CKD call into question whether there is a distinction between
early CKD and normal age-related decline in renal function. Reductions in renal blood flow
and mass, as well as increased glomerulosclerosis, are part of the normal ageing process,
with eGFR falling by about 0.75 mL/min/1.73 m2 per year from the age of 40.17 This rate of
progression seems non-linear, with eGFR loss in elderly patients slowing below 45 mL/min/
1.73 m2.18 In population studies, the majority of patients assigned as having CKD are aged
over 60 years, and most of these patients do not have significant albuminuria.19, 20 It is
therefore difficult to differentiate between age-related loss of kidney function and renal
disease.21 The data suggest that, for a given reduction in eGFR, elderly patients are less
likely to progress to ESRD.18, 22 The role of the ageing process has long been recognized for
other organ systems. For example, the natural decline in forced expiratory volume with age
forms a referent for the identification of premature or accelerated loss of respiratory
function.23
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Meta-analyses of over 1.5 million patients performed by the CKD Prognosis Consortium,
however, have shown almost identical risks for ESRD in patients above and below 65 years
of age with an eGFR of 45–59 and an ACR of <10 mg/g.24, 25 These data have been
interpreted as evidence against the introduction of differing thresholds for defining CKD
based on age, although the interaction between renal function and proteinuria does seem to
differ with age, potentially due to the competing risk for death. It has also been argued that
senescent changes in eGFR are due to other disease processes rather than pre-determined
renal decline.26, 27 The differing interpretations of the current data on eGFR loss in the
elderly underscore the need to consider eGFR trends as part of a clinical assessment.
Although it is unclear whether these eGFR changes reflect intrinsic renal disease or normal
ageing, CKD and senility are associated with an increased risk for morbidity and mortality
in an additive fashion.18
Comorbidity is common in CKD patients. In the UK, about 64% of patients aged over 65
years that are coded as having CKD have four or more additional morbidities.28 Whilst it is
acknowledged that multi-morbidity leads to greater need for healthcare, the risk factors for
multi-morbidity are ill-defined.29 Further work is required to determine whether renal
impairment in elderly patients is associated with or causes other conditions.
The formulae for estimating GFRs exhibit other well-documented limitations.30, 31 The
formulae were developed to identify patients with eGFR ≤60 mL/min/1.73 m2 at risk for
renal failure, and are not sensitive for stages 1 and 2.32 On their own, eGFR estimates are
therefore of little value in early intervention efforts; some have even called for removing the
first two stages from the KDOQI guidelines,33 while others have proposed alternative
classification systems.34 The MDRD Study equation tends to underestimate true GFR in
individuals with normal kidney function,35–38 while the CKD-EPI equation tends to
overestimate it in individuals with CKD or at high risk for CKD.39 The two equations only
generate eGFR figures that are within 30% of the true values. In 15.9% of CKD-EPI cases40
and 19.4% of MDRD Study cases,41 the estimated values are even less accurate. There are
also gender and ethnic differences in GFRs that should be accounted for.22, 33
Epidemiologic studies have used different eGFR formulae, which limits direct comparison
due to varying accuracies at higher levels of eGFR. Most national studies also rely on point
estimates of eGFR, whereas a CKD diagnosis should only be made after multiple estimates
over several months; results from point estimates tend to overstate prevalence rates.
Moreover, not all studies consider AER when estimating prevalence rates.
Cystatin-C-derived eGFR equations
The limitations of creatinine-based GFR estimates have resulted in investigation of other
molecules, including beta-trace protein42 and cystatin C.43 The latter molecule has been
shown to provide a more accurate estimates of renal function, including for elderly
patients,44–46 especially when used in combination with measurements of serum
creatinine;47 cystatin-C-derived formulas also seem to function well at high GFRs. The use
of these formulas is now recommended to confirm or exclude CKD in patients with mild
reductions in eGFR (creatinine) and an albumin creatinine ratio of <3mg/mmol.3, 48 This
strategy may lead to cost savings by reducing health-care use for inappropriately-diagnosed
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CKD. Although there is now an international standard for cystatin-C measurement, the assay
is not yet widely available. Diagnostic accuracy may improve if uptake of the assay
increases.
Albuminuria
Although AERs provide valuable diagnostic data, albuminuria tests also have limitations,
such as poor test-retest reliability,49, 50 further supporting the need to rely on more than one
prognostic factor. Albuminuria readings can vary depending on the type of assay (i.e.,
monoclonal vs. polyclonal),51 the sample collection method (i.e., 24-hour collection vs. first
morning void vs. random spot sample),52 and the storage procedure.53 Moreover, although
standard thresholds for pathological albumin excretion are used across gender and age, both
factors may affect urinary albumin measurement.54–56
Key points for clinical practice
Estimates of GFR that do not incorporate cystatin-C data are imprecise. This is often not
acknowledged in the literature, and even less so in clinical practice. Clinicians need to be
aware of the strengths and limitations of the diagnostic tools. Primary-care physicians
(PCPs) should rely on clinical judgment when evaluating individual patients based on eGFR
trends and albuminuria. Although these two parameters jointly provide accurate predictive
information about the risk of ESRD,57, 58 clinicians should also consider the severity of
comorbidities, family histories, and vascular risk profiles.59, 60 More work is needed to
improve the sensitivity and specificity of eGFR formulas and other risk equations for
progressive CKD.
How to define and manage early CKD?
As most CKD patients do not progress to ESRD, unselected treatment is neither clinically
appropriate nor, given the global scale of the disease, economically feasible. Clinical care
may improve if early-stage CKD with risk for progression towards ESRD is differentiated
from KDOQI stages 1–3 CKD that is unlikely to advance. Interventional studies may also
benefit from a more selective definition of early CKD. For example, the benefits of dietary
salt restrictions have still not been conclusively established,61 with a post-hoc analysis of the
ONTARGET and TRANSCEND studies finding no renal benefit in patients with early
CKD.62 Given the reported benefits of a low-salt diet in patients with advanced renal
failure,63 it is possible that specific phenotypes should be considered.
Screening debate
A systematic review commissioned by the US Preventive Services Task Force (USPSTF)
questioned the clinical and economic value of both screening the general population and
high-risk groups;64 this stance is supported by the American College of Physicians (ACP).65
The USPSTF review found no randomized controlled trials (RCTs) of “CKD screening in
adults who were asymptomatic with or without recognized risk factors for CKD incidence,
progression, or complications,” and no RCTs of “monitoring adults with CKD stages 1 to 3
for worsening kidney function or damage.”
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The position of the USPSTF and the ACP is not universally supported. In the UK, the
National Institute for Health and Care Excellence (NICE) advocates targeted assessment for
CKD in patients prescribed high-risk medications or with diseases linked to CKD (e.g.,
diabetes mellitus).48 The American Society of Nephrology (ASN) contends that universal
CKD screening is appropriate given the asymptomatic nature of mild-to-moderate CKD and
the ease with which investigation can be performed. Although the ASN acknowledges the
lack of RCT support for this position, they propose that early and better blood-pressure
control may slow progressive loss of renal function and that awareness of CKD may be
relevant during hospitalization episodes. A recent systematic review concluded that
proteinuria screening might be cost-effective in the diabetic and hypertensive populations.
The review also found that eGFR screening may be cost-effective in diabetic patients; there
were no cost-effectiveness studies of eGFR screening in hypertensive populations.66
Evidence gaps
The conflicting views of these stakeholders highlight the need for more RCTs of early CKD
identification, screening, monitoring, and treatment. In the meantime, population health
management could focus on vascular risk factor control and the CKD patients that are likely
to progress to ESRD and generate higher health-care costs.67, 68 Given the asymptomatic
and insidious onset of CKD, research into new biomarkers and prognostic techniques is
essential.69–71 It is an active area of research, and new prediction models are regularly
published.72–76 More work is needed to validate and refine these models. It is important to
examine the generalizability of findings across patient groups: while a model may be
appropriate for one patient population in one geographic region, it may be less accurate – or
even lead to erroneous conclusions – when applied for others.
Expanding the definition of early CKD must be considered in relation to the adverse
outcomes associated with reduced eGFR.77 Two recent meta-analyses by the CKD
Prognosis Consortium found that diabetic and hypertensive patients with reductions in eGFR
have increased risks of ESRD and death.78, 79 In both studies, the risk for ESRD
significantly rose once eGFRs dropped below 50 mL/min/1.73 m2. The risk for death,
however, increased below an eGFR of 90 mL/min/1.73 m2. Although these data could be
interpreted in support of defining mild reductions in renal function as part of a disease state,
it is important to consider the difference in threshold level of risk for death and ESRD.
These findings also raise the question of population versus individual risk, given that
patients with a low risk for ESRD still carry a potential risk for other complications.80 For
example, most new diagnoses of diabetes come from these low-risk groups.81 Screening
patients may therefore not contribute meaningful prognostic information at an individual
level regarding ESRD risk. Small reductions in eGFR have been shown to improve
discrimination in models of cardiovascular risk, and the rate of change in eGFR has been
considered a more potent predictor of risk than absolute values.82, 83
It is possible that what is currently labeled as CKD stage 1–2 should be assessed in relation
to cardiovascular risk rather than renal risk. This may particularly relevant when considering
the elderly population with reduced eGFR values but no significant albuminuria. In both
meta-analyses,78, 79 the risk of death and ESRD was associated with increased albuminuria
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in a linear manner, emphasizing the importance of this marker in defining risk for CKD
progression.
Management of early-stage CKD
There is a limited evidence base that lifestyle changes and the use of preventive medicines
can reduce the risk of cardiovascular disease and possibly slow, halt, or reverse CKD
progression during the early stages.1, 84 These data are generally of low quality, but they
provide some support for calorie-controlled diets,85–88, physical exercise,89–91 and smoking
cessation92–94; predominantly in diabetic CKD patients. Most CKD patients have
comorbidities that are amenable to a systematic approach to prevention and early
management, and many patients die from cardiovascular events or other causes before they
ever develop ESRD.59, 77, 95
The pathophysiology of increased vascular risk evolves over the natural history of CKD,96
with traditional atherosclerotic risk factors having a proportionately greater impact in early
stages. In early and pre-dialysis CKD,97, 98 treatment with lipid-lowering agents reduces risk
for cardiovascular events in spite of a lesser association between low-density lipoprotein
cholesterol (LDL-C) and patient outcomes in stages 3 through 5.99 Improved awareness of
CKD as a vascular risk factor would facilitate more timely usage of these agents alongside
better-known interventions such as blood-pressure control.100 The strongest evidence of
treatment benefit in patients with early CKD is from RCTs of angiotensin-converting
enzyme (ACE) inhibitors101 and angiotensin II-receptor blockers (ARBs).102, 103 However,
these studies focused on patients with proteinuric diabetic renal disease, and the data to
support the use of these agents for other causes of CKD are weaker.104
Recent data suggest that the rate of increase in the incidence of ESRD is slowing in some
countries, including Australia, Canada, northern European countries, New Zealand, and the
USA, although these trends vary by sub-groups (e.g., age and race).105 The stabilization of
these incidence rates may be due to better cardiovascular risk management in the diabetic,
hypertensive, and general populations, although this has yet to be shown conclusively.
Models of CKD care
The Wagner Chronic Care Model
There is some evidence106, 107 to suggest that the prevailing care strategy for CKD should
consist of three phases: (1) vascular risk management in primary care during early disease
(e.g., exercise, dietary changes, smoking cessation, blood pressure, glycemic and lipid
control, and periodic monitoring of kidney health); (2) structured care to target
comorbidities that develop in progressive cases (e.g., anemia, bone disease, and secondary
hyperparathyroidism); and (3) multi-professional, intensive care for patients transitioning to
renal replacement therapy. For all CKD patients, PCPs should check for drug interactions
that might cause acute kidney injury.
Based on the distribution of CKD cases across stages 1 through 5, almost all patients would
fall into the first phase. It is possible that CKD should be re-conceptualized as a part of
primary care,108 and that an integrated care approach should be adopted to coordinate the
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continuum of care for CKD patients (Box 1).109 This would be aligned with the Chronic
Care Model developed Dr. Edward H. Wagner, which consists of six core parts: community
resources and policies, health-care organization, self-management support, delivery system
design, decision support, and clinical information systems.110–113 These changes in clinical
practice are needed as the prevalence rates of diabetes and hypertension are expected to
increase,114–116 which will add to the CKD burden. A shift to a primary-care model might
enable nephrologists and other specialists to focus on patients with primary kidney disease,
rapidly progressing CKD, and ESRD.
PCPs should also carefully monitor the effect of certain types of drugs, contrast dyes, and
environmental toxins on the kidneys; this can be done with the help of IT systems. Some
prescription and over-the-counter medicines, such as non-steroidal anti-inflammatory drugs,
can precipitate acute kidney injury in CKD patients. Acute kidney injury can accelerate
CKD progression.117–119
Numerous studies have highlighted the shortcomings of primary care for CKD. Notably,
there is low awareness of the KDOQI guidelines and diagnostic techniques,120–125
suboptimal prescribing and management for diabetic and hypertensive patients,7, 124–129 and
poor recognition of known CKD risk factors.120 One study found that only 35% of PCPs had
“adequate knowledge” of CKD based on responses from 470 clinicians to a 27-question
survey; for each ten-year increase in age, the odds of having adequate knowledge decreased
by 26%.130 Another study found that only 19% of family practitioners and 33% of general
internists adhered to KDOQI guidelines on the laboratory and radiological evaluation of
patients with CKD.122 In a study commissioned by the US National Kidney Disease
Education Program, about one-third and one-fourth of PCPs did not recognize family history
and African-American race as CKD risk factors, respectively; however, there was high
awareness that diabetes and hypertension are predictors of CKD.120 These three
surveys120, 122, 130 were voluntary and had low response rates, ranging from 7.6% to 32.4%.
The participants may not be representative of the general PCP population. It is likely that
these findings – which already point to substantial room for improvement – overstate the
quality of CKD care.
The involvement of specialists in CKD care
Although the timely involvement of specialists is needed to improve health outcomes for
patients with progressive CKD, payers want to avoid unnecessary referral patterns that could
deplete resources. A systematic review of the clinical and cost-effectiveness evidence on
early versus late (or no) nephrologist referral found that early referral is associated with
better health outcomes and might be cost-effective.131 However, the authors did not find any
randomized-controlled trials that provide data on the clinical effectiveness of early-referral
strategies, and only two studies included pre-dialysis patients. The authors noted that there
are insufficient data on the natural history of CKD and the costs and effects of early referral.
They highlighted the need for long-term observational studies of early-CKD patients to
better delineate disease progression and the incidence of cardiovascular events in patients
with and without related health conditions, such as diabetes, pre-existing cardiovascular
disease, albuminuria, and proteinuria. The authors also suggested that the large costs of early
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referral may be unaffordable for health systems, even if early referral is cost-effective.
Further research is needed to evaluate the cost-effectiveness of improved primary care for
early-CKD patients.
PCPs should be involved in re-defining CKD to facilitate a paradigm shift. In the UK, early
identification of CKD is financially incentivized in primary care, but some PCPs express
concern over whether CKD is a genuine disease state.132 In areas where patients are not
correctly identified on CKD registers, cardiovascular management has been shown to be
suboptimal, with worse blood-pressure and cholesterol control.133 A transition to a primary-
care model should be a universal decision, unlike the development of current guidelines
which has been driven by secondary-care providers.134
Integrated care pathways for CKD
A unified patient-care strategy across health-care providers and payers might improve
health-care outcomes. It is important to evaluate models of CKD care in terms of value for
money and to understand what approaches achieve reliable service delivery to high-risk
populations. CKD can provide a useful case study of how to implement a shift to a primary-
care model that is public-health oriented, proactive, and patient-centered.
USA
Despite the fragmentation of the US health system, positive CKD trends have been observed
in some public (Indian Health Service135, 136 and Veterans Health Administration137) and
private health-care organizations (Kaiser Permanente138, 139). The long-term focus of the
Indian Health Service and Veterans Health Administration – patients usually remain with
each agency their entire lives – encourages preventive care. In the Indian Health Service, an
important intervention was the widespread use of ACE inhibitors in the early 1990s. Today,
about 80% of hypertensive patients with diabetes in this population receive ACE inhibitors.
The growth in CKD and ESRD rates is slowing quicker among these patients than in the
general population.135, 136 The Indian Health Service experience has demonstrated that a
system-wide approach, even in an underfunded system, can produce significant benefits.
Kaiser Permanente of Southern California, a vertically-integrated health maintenance
organization in the US, has deviated from the KDOQI guidelines.139 The organization
instead applies a composite risk assessment to target patients whose conditions are expected
to worsen, and it uses IT systems that automatically recommend treatment options based on
patient information. The Hawaiian network of the organization has also started providing
care to CKD patients based on risk stratification, and has found that this approach is
associated with a statistically-significant reduction in disease progression.138
UK
In the UK, there is growing integration between primary and secondary care. A 2003 study,
which preceded automated eGFR reporting, reviewed the electronic primary care records of
over 130,000 patients and found high rates of undiagnosed CKD.140 While automated eGFR
reporting has improved recognition of CKD in primary care and has increased referral rates,
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this study also suggests that it is possible to alert PCPs about missed opportunities for
preventive prescribing.
A similar model of CKD management to the one introduced by Kaiser Permanente138 was
phased in between 2003 and 2006 in the West Midlands region of England. Early results
show that patient outcomes have improved, including a reduction in the population-adjusted
incidence of renal replacement therapy.141 Another study evaluated the health outcomes of
patients with CKD stages 4–5 treated in primary care with a disease management program;
the program was similar to a secondary care multi-disciplinary clinic. The study found that
the program improved health outcomes and reduced eGFR loss over a nine-month period.142
Intensive, target-driven disease management programs have produced positive outcomes in
diabetes care,143 and there is the potential for such approaches to be applied to CKD care.
Other international experiences
Other countries, including Australia and Canada, are transitioning to primary-care models
for CKD in the general population. Similarly to the Indian Health Service, Australia has also
long relied on community-based CKD care for the population of the Tiwi Islands, an
aboriginal community. The Tiwi Islands model focuses on blood-pressure and lipid control
and health education to try to improve cardiovascular health and preserve renal function.
The published data suggest that this strategy has markedly improved cardiovascular and
renal health outcomes in this population.144 These international experiences suggest that a
holistic care model can be successfully applied across different types of health systems.
Systems modeling
As previously described, physicians should consider the limitations of population-based
estimating equations and evaluate individual patient characteristics when predicting risk and
developing treatment plans. Structured, early CKD intervention programs can form the basis
for such personalized care. Given the heterogeneity of patients with early CKD, and the
variable risks in different population segments, clarity on the appropriate scope and impact
of such programs is needed. Health-care providers, payers, and the general public need to
know whether it is cost-effective or not to invest in CKD intervention programs.
Systems modeling is an inexpensive method to study the effects of different interventions on
chronic-disease outcomes and costs.145–147 The software can be used to design
comprehensive care models in patient populations and observe the diabetes, hypertension,
CKD, and ESRD burdens over time. Systems modeling allows for sensitivity analysis to test
the degree of uncertainty around the model assumptions. This can give an indication of the
reliability and strength of the results, and highlight areas where more research is needed.
Alongside systems modeling, long-term prospective cohort studies are needed to understand
the clinical and economic value of different intervention strategies from a payer or societal
perspective. Ideally, these studies should incorporate RCTs of CKD treatments into the
study designs. It is also important to conduct economic analyses alongside outcome
evaluations. Notably, the Nord-TrØndelag Health Study (HUNT) in Norway,148 the
aforementioned Kaiser Permanente139 and English West Midlands141 studies, and most
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CKD quality improvement studies do not consider costs. If health-economic evaluations
were built into these population-based studies, it would generate useful evidence to guide
care approaches. Relevant stakeholders should also establish registries to monitor the long-
term health and cost effects of different care pathways and timing of care initiation.
Conclusion
There is insufficient evidence on the clinical and economic benefits of early CKD
intervention, especially in comparison to diseases like diabetes and stroke. There are no
RCTs of the clinical and cost outcomes of early intervention strategies, and comprehensive
patient-level data are not readily accessible. However, it is possible that early diagnosis,
treatment, and management of CKD could alter the natural history of the disease and
generate substantial cost savings. A better understanding of the merits and demerits of
different care approaches for CKD, and where evidence is lacking, is essential to improve
health outcomes and to minimize expenditure.
CKD, like many chronic conditions, is in essence a broad indicator of overall health.
Patients with mildly or moderately depressed eGFRs usually have comorbidities that are
more relevant to their current and future well-being than a CKD diagnosis. These
comorbidities should remain the focus of treatment and management, as few patients who
are diagnosed with CKD develop ESRD.
The difficulty for physicians to identify progressive CKD patients has weakened the
effectiveness of early interventions. Although new biomarkers that may improve CKD
detection and prognosis are becoming increasingly available, it is unlikely that any silver
bullet will fully address the disease burden of CKD. It is important to promote a unified care
strategy across health-care providers and payers. This holds true for CKD, a particularly
complex disease involving many providers over a patient's lifetime, but also applies to other
chronic illnesses.
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Box 1. Prevention strategies for early-stage CKD
Primary and secondary
• Clarification of CKD staging and prognostication to improve PCP engagement
• Patient and clinician education to link public health programs to kidney health
Target population
• Development of high-quality evidence to guide screening programs for CKD
and RCTs
• Patients at risk of AKI or with previous AKI
• Continued assessment of high-risk populations
Impact assessment
• Assessment of patient awareness of disease and personal clinical data
• Proportion of patients experiencing cardiovascular events, a preventable loss of
renal function, or requiring referral to secondary care
Abbreviations: AKI, acute kidney injury; CKD, chronic kidney disease; PCP, primary
care physician; RCT, randomized controlled trial.
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Box 2. Service delivery for CKD
Primary care
• Patient assessment by eGFR trend and/or trajectory reporting
• Classification of CKD based on risk for progression
• Identification of CKD as an indicator for elevated cardiovascular risk, with early
modification of traditional risk factors
• Patient advocacy and self-management during early-stage CKD
• Referral to secondary care for specialist treatment of CKD complications
Secondary care
• Multidisciplinary management of disease complications
• Ongoing support for patient self-management programs
• Integration with other secondary care services to manage the burden of
comorbidities
• Personalized treatment goals with consideration of quality of life
• Integration into primary care to support periodic monitoring of stable patients by
PCPs
• Structured follow-up for patients having experienced AKI, with data collection
to describe long-term effects on GFR trajectory
Abbreviations: AKI, acute kidney injury; CKD, chronic kidney disease; eGFR, estimated
glomerular filtration rate; PCP, primary care physician.
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Box 3. Workforce, ICT, and other strategies to improve care for early-stage
CKD
Workforce
Essentials and supportive
• Motivated and educated workforce and patient population
• Easy access to laboratory monitoring
• Specialist nursing staff to support patient understanding of the disease
• Financially viable secondary care renal services for a potentially smaller but
very ill patient population
PCP-specialist interface
• Multi-specialty clinics in primary care to support PCP education and patient
care
• Defined referral and discharge criteria for secondary care
Role of ICT and decision-support systems
• Integration of primary and secondary care records
• Accessible results reported to patients in any location
• Automated analysis of eGFR and/or trends in proteinuria
• Incorporation of validated predictive models for ESRD into laboratory reports
• Electronic prescribing linked to biochemical results
Health-economic impact and health-system financing
• Economic analyses built into all studies of CKD screening and treatment
• Financial incentives balanced towards prevention of progression to ESRD
• The establishment of CKD registries to permit health-economic analyses
Leadership, governance, and role of national and international organizations
• International, evidence-based accordance between national and international
bodies regarding CKD screening and treatment
• Increased data sharing between health systems of epidemiologic trends in CKD
• Strong patient representation in all organizations
Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate;
ESRD, end-stage renal disease; ICT, information and communications technology; PCP,
primary care physician.
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Figure 1.
The prevalence of CKD by stage in the USA, 1988–2012. The prevalence estimates are
based on samples of non-institutionalized adults (aged 20 years or older) who participated in
the National Health and Nutrition Examination Survey (NHANES) during the study years.
The sample sizes varied across 1988–1994 (n=15,488), 1999–2004 (n=13,233), and 2007–
2012 (n=15,502). The proteinuria measures were based on albumin-creatinine ratios from
spot morning urine samples. The estimated glomerular filtration rates were calculated using
the CKD-EPI creatinine formula. Stage 3 corresponds to a glomerular filtration rate of 30-59
mL/min/1.73 m2. The error bars show the 95% confidence intervals. The data reported here
have been supplied by the United States Renal Data System (USRDS). The interpretation
and reporting of these data are the responsibility of the authors and in no way should be seen
as an official policy or interpretation of the U.S. government.
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Figure 2.
The breakdown of CKD by stage (1–5) in selected countries with data available from the
2000's. Stage 3 corresponds to a glomerular filtration rate of 30-59 mL/min/1.73 m2. The
Chinese study used a sample of individuals from Beijing, the Indian study used a sample
from thirteen academic and private medical centres located throughout the country, and the
Korean study used a sample from seven urban cities. The other studies used nationally-
representative samples. For Japan, the prevalence estimate for stage 4 includes both stages 4
and 5. All studies either sampled adults aged ≥18 years or ≥20 years, except for the Korean
study which included adults aged ≥35 years. All studies used a version of the four-variable
MDRD study equation to determine eGFR, except for the USA study data which used the
CKD-EPI creatinine formula. The Chinese, Korean, Spanish, and USA studies measured
proteinuria by using the spot morning urinary albumin-creatinine ratio. The remaining
studies used a urine dipstick analysis for proteinuria. The Chinese study also measured
haematuria by dipstick test.
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Figure 3.
Comparison of CKD prevalence by eGFR formula (CKD-EPI creatinine vs. four-variable
MDRD study) in the USA, 1999–2004. The prevalence estimates are based on samples of
non-institutionalized adults (aged 20 years or older) who participated in the National Health
and Nutrition Examination Survey (NHANES) during these years (n=13,233). The CKD-
EPI data reported here have been supplied by the United States Renal Data System
(USRDS). The interpretation and reporting of these data are the responsibility of the authors
and in no way should be seen as an official policy or interpretation of the U.S. government.
The four-variable MDRD study data were reported by Coresh et al (2007). Both studies used
measures of albumin-creatinine ratios from spot morning urine samples. Stage 3 corresponds
to a glomerular filtration rate of 30–59 mL/min/1.73 m2. The error bars show the 95%
confidence intervals. Coresh et al (2007) did not estimate the prevalence of stage 5 with the
MDRD study equation as they deemed that “estimates of this stage are likely to be
unreliable due to the small number of individuals and the likelihood that many of these
individuals are ill or receiving dialysis and would have a low response rate.”
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Figure 4.
An integrated care continuum for CKD that is consistent with the chronic care model.
Abbreviations: AVF, arteriovenous fistula; CKD, chronic kidney disease; ESRD, end-stage
renal disease; RRT, renal replacement therapy.
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Table 1
Definition and classification of CKD
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